Genetic and epigenetic discoveries hold promising avenues in cardiovascular disorders prevention and management by using gene therapy.
Moataz Dowaidar
Abstract
These recent genetic and epigenetic discoveries hold promising avenues incardiovascular prevention and management (CVDs) Currently, key nucleic acidsare being researched and developed for medicinal use. The trial was onlydesigned to be to an extent that would satisfy the demands ofbiopharmaceutical/industrial development.determinants in clinical trials, and of ASO and siRNA previously developedantisense oligonucleotides for cardiovascular disease. Advanced nucleic acidchemistry produces nucleic acid compounds that maintain key structuralattributes of RNA or DNA. Modifications of the backbone also improved thedrug-receptor specificity and decreased protease activityASOs for Apo (a) targeting Lp (a) and the production of other similar therapiesare currently available or will soon be available. It is a second-generation ASOcalled Volens which has been approved in Europe for chylothoriamiasiscontributing to hemangiomas and rheumatoidensisitum rather than to treatprotein CVD. TASO produces a significant reduction in wild-type and mutantTTR ASO options that target dystrophy have been evaluated in humans.Both siRNA and CRISPR have a long, long history, but these protection aspectsneed to be worked out first. (currently) of concern: chemically synthesized siAs,recombinanted si an RNA-induced silencing complex (RISC) utilizes Argona(A) to synthesize siRNAs